The pathology of bladder cancer: An update on selected issues

BJU International

Volumn 98, Issue 6, 2006, Pages 1161-1165

  Pavone Macaluso, Michele ^a,e   Lopez Beltran, Antonio ^b   Aragona, Federico ^a   Bassi, Pierfrancesco ^c   Fitzpatrick, John M ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bladder cancer; Grading; Markers; Staging

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

BLADDER CANCER; CANCER GRADING; CARCINOGENESIS; CHROMOSOME 9; CLINICAL PRACTICE; CONSENSUS; DOWN REGULATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MEDICAL SPECIALIST; METABOLISM; METASTASIS; MOLECULAR DYNAMICS; NOMENCLATURE; PATHOLOGIST; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SHORT SURVEY; TRANSURETHRAL RESECTION; TUMOR BIOPSY; UROLOGY; WORLD HEALTH ORGANIZATION;

BIOPSY, NEEDLE; HUMANS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33750888342     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06445.x     Document Type: Short Survey

References (24)

1. Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter and renal pelvis. Eur Urol 2004; 45: 257-66
2. UICC: International Union Against Cancer. TNM Classification of Malignant Tumours . Berlin: Springer-Verlag, 2002
3. UICC: International Union Against Cancer. Sobin LH, Wittekind CH eds, TNM Classification of Malignant Tumours. 6th edn. New York: Wiley-Liss, 2002
4. Boccardo F, Silvestrini R eds. 'Basi Scientifiche Per la Definizione Di Linee Guida in Ambito Clinico Per I Tumori Della Vescica'. Progetto Strategico Oncologia. Rome: CNR (National Research Council) and MIUR (Italian Ministry for University and Research), July 2005
5. Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 1840-6
6. Sylvester R, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77
7. Mostofi FK, Sobin LH, Torloni H. Histological Typing of Urinary Bladder Tumours. Geneva: World Health Organization, 1973
8. Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG. Classification and grading of the noninvasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 2003; 56: 91-5
9. Malmström PU, Busch C, Norlén BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21: 185-95
10. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, Chapter 2. Lyon: IARC Press, 2004
11. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002; 441: 105-8
12. Montironi R, Bassi PF. Urothelial bladder tumours. The Ancona 2001 refinement of the WHO 1973 classification. Guonews 2002; 3(Suppl.): 1-6
13. Lopez-Beltran A, Cheng L, Andersson L et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002; 440: 3-11
14. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004; 46: 170-6
15. Montironi R, Scarpelli M, De Nictolis M, Mariuzzi GM, Ansuini G, Pisani E. Comparison of computerized analysis of nuclear DNA changes in uterine cervix dysplasia and in urothelial non-invasive papillary carcinoma. Pathol Res Pract 1988; 183: 489-96
16. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta, T1 bladder tumours: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTCGU Group Superficial Bladder Committee. Eur Urol 1999; 35: 267-71
17. May F, Treiber U, Hartung R, Schweibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol 2003; 44: 47-50
18. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66(Suppl. 6A): 4-34
19. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-9
20. Jakse G, Algaba F, Malmström PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: Why? Eur Urol 2004; 45: 539-46
21. Jahnson S, Wiklund F, Duchek M et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005; 39: 206-10
22. Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International consensus panel on bladder tumor markers. Urology 2005; 66(Suppl. 6A): 64-74
23. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, 21Waf1, 27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004; 122: 444-52
24. Gontero P, Tizzani A, Muir GH, Caldarera E, Pavone-Macaluso M. The genetic alterations in the oncogenic pathway of transitional cell carcinoma of the bladder and its prognostic value. Urol Res 2001; 29: 377-87